Delayed Cystoscopic Follow-up of Non-muscle Invasive Bladder Cancer during the COVID-19 Pandemic may Increase Recurrence Rates but not Progression Rates

Year 2023, Volume: 5 Issue: 4, 248 - 253, 29.10.2023

Yavuz Bastug , Aykut Çolakerol

https://doi.org/10.46310/tjim.1345635

Abstract

Background: This study aimed to investigate whether there is a difference in recurrence and progression rate before and after the pandemic in patients who applied for bladder cancer and/or were followed-up-treatment-operated in the urology clinic during the pandemic.
Material and Methods: A total of 116 non-muscle invasive bladder cancer (NMIBC) patients with delayed cystoscopy and 90 control patients with timely cystoscopy were included in the study between June and July 2020. Demographic data of the patients were recorded. Recurrences and progression scores were calculated and grouped according to these scores. The cystoscopy delay time was calculated from the planned cystoscopy time to the performed cystoscopy time. The recurrence and progression status of the patients were recorded, and a comparison was made between the two groups.
Results: The median age was 63.6 years (interquartile range [IQR] 35–85) in the delayed cystoscopy group and 67.3 (25-87) in the control group. In the delayed cystoscopy group, 29 (25%) patients had tumour recurrence on follow-up cystoscopy, and 3 (10.34%) patients had tumour progression on subsequent TUR-BT. The mean cystoscopy delay time is 89.27±27.35 days. As a result of the chi-square analysis performed on the group with 10-17 recurrence points found a statistically significant relationship between the experimental and control groups (χ2=5.792; p=.016; p<0.05). As a result of the chi-square analysis between the experimental and control groups according to the progression score groups, no statistically significant correlation was found between the experimental and control groups (p>0.05).
Conclusions: In this study, we reported that superficial bladder cancers with low recurrence scores could wait 3-6 months, but delaying 3-6 months in cases with a recurrence score of 10 or more increases the recurrence rate.

Keywords

bladder cancer, delay, follow-up, recurrence, progression

References

• Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20. doi: 10.1056/NEJMoa2002032
• Stensland KD, Morgan TM, Moinzadeh A, Lee CT, Briganti A, Catto JWF, Canes D. Considerations in the triage of urologic surgeries during the COVID-19 pandemic. Eur Urol. 2020 Jun;77(6):663-6. doi: 10.1016/j.eururo.2020.03.027.
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210.
• Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, Houéde N, Roy C, Durand X, Varinot J, Vordos D, Rouanne M, Bakhri MA, Bertrand P, Jeglinschi SC, Cussenot O, Soulié M, Pfister C. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015 May;466(5):589-94. doi: 10.1007/s00428-015-1739-2.
• Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. doi: 10.1016/j.eururo.2005.12.031.
• Narain TA, Gautam G, Seth A, Panwar VK, Rawal S, Dhar P, Talwar HS, Singh A, Jaipuria J, Mittal A. Uro-oncology in times of COVID-19: The available evidence and recommendations in the Indian scenario. Indian J Cancer. 2020 Apr-Jun;57(2):129-38. doi: 10.4103/ijc.IJC_356_20.
• Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol. 2004 Aug;46(2):170-6. doi: 10.1016/j.eururo.2004.03.017.
• Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003 Aug;170(2 Pt 1):438-41. doi: 10.1097/01.ju.0000076621.71247.6c.
• Marcq G, Hénon F, Ouzaid I, Fantoni JC, Hermieu JF, Xylinas E. Active surveillance for non-muscle invasive bladder cancer. Transl Androl Urol. 2019 Feb;8(1):54-60. doi: 10.21037/tau.2018.10.20.
• Hernández V, Llorente C, de la Peña E, Pérez-Fernández E, Guijarro A, Sola I. Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. Urol Oncol. 2016 Apr;34(4):165.e19-23. doi: 10.1016/j.urolonc.2015.11.005.
• Hurle R, Lazzeri M, Vanni E, Lughezzani G, Buffi N, Casale P, Saita A, Morenghi E, Forni G, Cardone P, Lista G, Colombo P, Peschechera R, Pasini L, Zandegiacomo S, Benetti A, Maffei D, Vavassori I, Guazzoni G. Active surveillance for low risk nonmuscle invasive bladder cancer: A confirmatory and resource consumption study from the BIAS project. J Urol. 2018 Feb;199(2):401-406. doi: 10.1016/j.juro.2017.08.091.
• Maccagnano C, Rocchini L, Montanari E, Conti GN, Petralia G, Dehò F, Bryan KA, Contieri R, Hurle R. Overview of the Italian experience in surgical management of bladder cancer during first month of COVID-19 pandemic. Arch Ital Urol Androl. 2020 Dec 17;92(4). doi: 10.4081/aiua.2020.4.275.
• Wang T, Liu S, Joseph T, Lyou Y. Managing bladder cancer care during the COVID-19 pandemic using a team-based approach. J Clin Med. 2020 May 22;9(5):1574. doi: 10.3390/jcm9051574.
• Culpan M, Keser F, Acar HC, Otunctemur A, Kucuk EV, Erdem S, Ozer M, Sen UT, Degirmenci E, Ergul R, Atis RG, Yildirim A. Impact of delay in cystoscopic surveillance on recurrence and progression rates in patients with non-muscle-invasive bladder cancer during the COVID-19 pandemic. Int J Clin Pract. 2021 Sep;75(9):e14490. doi: 10.1111/ijcp.14490.